ArticleTranslational andrology and urology2020
Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030.
Article in Translational andrology and urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature.Prostate cancer and prostatic diseases · 2021Pooled it
- Trends and projections in prostate cancer epidemiology in Thailand: A population-based cancer registry analysis.Asian journal of urology · 2026Article
- Racial disparities in the receipt of therapies for cancer, hypertension, and diabetes, and in mortality in a large population-based cohort of older men with prostate cancer.Ethnicity & health · 2025Article
- Global epidemiological trends in prostate cancer burden: a comprehensive analysis from Global Burden of Disease Study 2021.Translational andrology and urology · 2025Article
- Prostate Cancer Mortality in Iranian Men During 1990-2021: An Age-Period-Cohort and Joinpoint Regression Analysis.Prostate cancer · 2025Article
- Real world prevalence of pelvic lymph node involvement in prostate cancer in Asia: do we need a rethink on normograms?Frontiers in oncology · 2025Article
- Comparative Cardiovascular Risks of Radical Prostatectomy and External Beam Radiation Therapy in Early-Stage Prostate Cancer: A Comprehensive Retrospective Analysis.Annals of surgical oncology · 2024Article
- Developing a Core Outcome Set for Assessing Clinical Safety Outcomes of Prostate Cancer in Clinical Trials of Traditional Chinese Medicine: Protocol for a Mixed Methods Study.JMIR research protocols · 2023Article
- Developing machine learning algorithms for dynamic estimation of progression during active surveillance for prostate cancer.NPJ digital medicine · 2022Article
- ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARDTranslational andrology and urology · 2022Article
- The treatment landscape of metastatic prostate cancer.Cancer letters · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis research aims to identify the current and future trends in the incidence and death rate of prostate cancer and to provide the necessary data support for making relevant health decisions.
methodsThis study used the collected data and methodologies to describe the incidence and mortality trends of prostate cancer from 1990 to 2016. Based on the data, this paper projected the future trends in prostate cancer incidence and death rate.
resultsIn 2016, prostate cancer cases [1,435,742; 95% uncertainty interval (UI), 1,293,395-1,618,655] were nearly 2.5-fold the number in 1990 (579,457; 95% UI, 521,564-616,107). Deaths increased by 2.0-fold from 191,687 (95% UI, 168,885-209,254) in 1990 to 380,916 (95% UI, 320,808-412,868) in 2016. The global age-standardized incidence rate (ASIR) increased from 17.75 (95% UI, 18.91-15.95) in 1990 to 22.12 (95% UI, 19.92-24.91) in 2016, changing 24.62%. The global change of age-standardized death rate (ASDR) has declined slightly, but in some regions it shows a trend of growth. By sociodemographic index (SDI) sub-types, prostate cancer will frequently occur in high SDI countries from 1990 to 2030. Simultaneously, the highest mortality will present in low SDI countries.
conclusionsThrough projecting and analyzing incidence and mortality rate of prostate cancer, from 1990 to 2030, by different ages, regions and SDI sub-types, this result may reveal the relationship between prostate cancer and financial development. At the same time, the result also showed a sufficiently heavy burden of prostate cancer, but the burden varies greatly in each region. The burden is a challenge and will require attention for all levels of society. The current study is beneficial to formulate more specific and efficient policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.